“…Despite the fact that the overwhelming majority of available literature favors the second scenario by showing multiplicity of HPMC-driven activities that contribute to ovarian cancer progression both in vitro and in vivo [5,[12][13][14], there is still a fallacy pointing to the protective role (as a "barrier") of HPMCs [2,3,15]. The rationale for the latter is, however, strange, since the lack of mesothelium under the ovarian tumor mass due to its retraction via cancer spheroid myosin-generated forces [3] does not mean that these cells were unable to initially exert (when still present, especially at the time of cancer adhesion) certain procancerogenic effects.…”